Opus Genetics Net Profit Margin 2010-2024 | IRD

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Opus Genetics net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Profit Margins Gross Margin Operating Margin EBITDA Margin Pre-Tax Margin Net Margin

Opus Genetics net profit margin from 2010 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$155.8B
Bristol Myers Squibb (BMY)	$118.1B
Vertex Pharmaceuticals (VRTX)	$116B
Gilead Sciences (GILD)	$111.9B
CSL (CSLLY)	$86.5B
Regeneron Pharmaceuticals (REGN)	$81.8B
GSK (GSK)	$69.8B
Argenex SE (ARGX)	$35.7B
Alnylam Pharmaceuticals (ALNY)	$31.8B
BioNTech SE (BNTX)	$25.9B
Biogen (BIIB)	$23B
Illumina (ILMN)	$21.7B
BeiGene (BGNE)	$18.9B
Moderna (MRNA)	$14.7B
Incyte (INCY)	$13.6B
Genmab (GMAB)	$13.5B
Insmed (INSM)	$13.2B
BioMarin Pharmaceutical (BMRN)	$12.1B
Bio-Techne Corp (TECH)	$11.3B
Vaxcyte (PCVX)	$11B
Sarepta Therapeutics (SRPT)	$10.6B
Exelixis (EXEL)	$9.9B
Exact Sciences (EXAS)	$9.8B
QIAGEN (QGEN)	$9.7B
Revolution Medicines (RVMD)	$9.6B
Bio-Rad Laboratories (BIO.B)	$9.4B
Intra-Cellular Therapies (ITCI)	$9.1B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.9B
Ascendis Pharma (ASND)	$7.4B